Article Text

Original research
PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin
  1. Diana Canals Hernaez1,
  2. Michael R Hughes1,
  3. Pamela Dean2,
  4. Peter Bergqvist3,
  5. Ismael Samudio3,
  6. Ola Blixt4,
  7. Katharina Wiedemeyer5,
  8. Yicong Li1,
  9. Chris Bond3,
  10. Eric Cruz3,
  11. Martin Köbel5,
  12. Blake Gilks6,
  13. Calvin D Roskelley2 and
  14. Kelly M McNagny1
  1. 1 The Biomedical Research Centre and School of Biomedical Engineering, The University of British Columbia, Vancouver, British Columbia, Canada
  2. 2 Department of Cellular and Physiological Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
  3. 3 Centre for Drug Research and Development, Vancouver, British Columbia, Canada
  4. 4 Copenhagen Center for Glycomics and Department of Cellular and Molecular Medicine (ICMM), University of Copenhagen, Kobenhavn, Denmark
  5. 5 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
  6. 6 Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada
  1. Correspondence to Professor Kelly M McNagny; kelly{at}


Background The success of new targeted cancer therapies has been dependent on the identification of tumor-specific antigens. Podocalyxin (Podxl) is upregulated on tumors with high metastatic index and its presence is associated with poor outcome, thus emerging as an important prognostic and theragnostic marker in several human cancers. Moreover, in human tumor xenograft models, Podxl expression promotes tumor growth and metastasis. Although a promising target for immunotherapy, the expression of Podxl on normal vascular endothelia and kidney podocytes could hamper efforts to therapeutically target this molecule. Since pathways regulating post-translational modifications are frequently perturbed in cancer cells, we sought to produce novel anti-Podxl antibodies (Abs) that selectively recognize tumor-restricted glycoepitopes on the extracellular mucin domain of Podxl.

Methods Splenic B cells were isolated from rabbits immunized with a Podxl-expressing human tumor cell line. Abs from these B cells were screened for potent reactivity to Podxl+ neoplastic cell lines but not Podxl+ primary endothelial cells. Transcripts encoding heavy and light chain variable regions from promising B cells were cloned and expressed as recombinant proteins. Tumor specificity was assessed using primary normal tissue and an ovarian cancer tissue microarray (TMA). Mapping of the tumor-restricted epitope was performed using enzyme-treated human tumor cell lines and a glycan array.

Results One mAb (PODO447) showed strong reactivity with a variety of Podxl+ tumor cell lines but not with normal primary human tissue including Podxl+ kidney podocytes and most vascular endothelia. Screening of an ovarian carcinoma TMA (219 cases) revealed PODO447 reactivity with the majority of tumors, including 65% of the high-grade serous histotype. Subsequent biochemical analyses determined that PODO447 reacts with a highly unusual terminal N-acetylgalactosamine beta-1 (GalNAcβ1) motif predominantly found on the Podxl protein core. Finally, Ab–drug conjugates showed specific efficacy in killing tumor cells in vitro.

Conclusions We have generated a novel and exquisitely tumor-restricted mAb, PODO447, that recognizes a glycoepitope on Podxl expressed at high levels by a variety of tumors including the majority of life-threatening high-grade serous ovarian tumors. Thus, tumor-restricted PODO447 exhibits the appropriate specificity for further development as a targeted immunotherapy.

  • antigens
  • tumor-associated
  • carbohydrate
  • genital neoplasms
  • female
  • tumor biomarkers
  • translational medical research
  • epitope mapping

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Ovarian carcinoma (OC) is one of the leading causes of cancer mortality in women.1 Frequently diagnosed only at advanced stages and with a 5-year survival of approximately 47%,2 OC is a ‘silent killer’ that offers few treatment options. Although new diagnostic and treatment options have led to a significant improvement in survival rates for many cancers over the last 50 years, the 5-year survival for OC has hardly changed since 1980,3 4 highlighting the urgent need for new treatment strategies.

Although genetic and/or epigenetic changes are known to drive tumor development, dysregulation of protein expression and altered post-translational modifications are also known to occur. Specifically, changes in the patterns of protein glycosylation are well known to occur in cancer5 and, in some cases, are thought to drive tumor progression.6 This can be through well-known effects on protein stability and folding; or through modification of processes including protein trafficking, immune recognition, cell migration, ligand–receptor interaction, signal transduction and cell adhesion.7–11 Indeed, glycans can confer a selective advantage on cells that facilitates tumor spread.12 13 Moreover, cancerous cells undergo reprograming and transcriptional changes that greatly impact their glycome and glycoproteome, leading to overexpression or de novo expression of specific glycoepitopes. Importantly, these cancer-specific alterations in protein glycosylation may also provide a unique opportunity for clinical intervention with reduced toxicity since these modifications are largely tumor-specific.

Podocalyxin (Podxl) is a member of a 3-gene family of stem cell sialomucins that includes Podxl, CD34 and endoglycan. These proteins can be distinguished from other cell surface sialomucins based on a shared genomic organization (each encoded by a similar, 8-exon, genomic locus) and a shared protein domain structure: they each contain a large, highly glycosylated mucin domain followed by a cysteine-bonded globular domain, stalk domain, transmembrane domain and a short (approximately 70 amino acid) cytoplasmic tail with a consensus C-terminal binding site for PDZ-domain proteins.14–16 Although widely expressed during embryonic development,15 17 in normal adult tissue Podxl is primarily expressed on vascular endothelia,18 19 kidney podocytes15 and a restricted subset of epithelial lumens.15 Nevertheless, Podxl is also aberrantly expressed by a wide variety of cancer types, and this expression is consistently an indicator of poor prognosis.20–30 For example, in early retrospective studies of breast cancer, patients with tumors expressing high levels of Podxl exhibited a greatly reduced disease-specific survival, and multivariant analysis showed Podxl to be a highly-significant independent predictor of poor outcome.20 Similarly, in OC where Podxl is expressed by the majority of high-grade serous carcinomas, cell surface expression of Podxl correlated with a significant decrease in disease free survival.22 Interestingly, recent gene silencing experiments suggest that upregulation of Podxl is not merely a predictor of poor outcome but also an important player in disease progression by enhancing tumor invasion and metastasis.21 29 31 32 In summary, because of its cell surface localization and its direct role in tumor metastasis, Podxl is a promising target for cancer immunotherapy.

As a first foray into exploiting this opportunity, we generated a series of anti-Podxl monoclonal antibodies (mAbs) to the extracellular domain of Podxl expressed on the surface of tumor cells.21 One mAb, PODOC1 (hereafter designated PODO83), showed a potent ability to restrict primary tumor growth in vivo and to block metastatic progression when administered to tumor bearing mice.21 While PODO83 harbors tremendous potential as a therapeutic, its ability to recognize the stalk domain of the Podxl core protein poses a possible risk of toxicity due to its reactivity with normal kidney podocytes and vascular endothelia.

Intriguingly, however, Podxl is known to undergo tissue-specific glycosylation,30 a process that is frequently altered in cancer.6 33 34 Accordingly, to circumvent the potential toxicity associated with Abs reactive to the core polypeptide, we carefully rescreened our panel of anti-Podxl Abs for those that react selectively with a tumor-restricted glycoform of Podxl but not with normal tissue. Here, we report the identification of PODO447, a novel mAb with exquisite specificity for a tumor-specific glycoepitope on Podxl. As such, PODO447 offers a unique opportunity to selectively target tumor tissue while sparing normal tissue and highlights its promise as a therapeutic.


Ab production

New Zealand White rabbits were immunized with Podxl-expressing human glioblastoma A-172 cells (#CRL-1620, American Tissue Culture Collection (ATCC)). Rabbit mAbs were isolated using selected lymphocyte antibody method (SLAM) technology.35 Briefly, individual B-cell clones whose supernatants reacted with Podxl-expressing MDA-MB-231 cells were selected. These were then screened via ELISA for high reactivity against Podxl isolated from human breast cancer MDA-MB-231 and low reactivity to the human embryonic kidney 293 (HEK 293) cells. Next, selected clones were screened against Podxl-expressing MDA-MB-231 and its PODXL-KO counterpart to confirm Podxl specificity. Supernatants were also screened for reactivity with Chinese hamster ovary (CHO) cells expressing Podxl, and low reactivity to CHO cells expressing related family members CD34 (Cd34) and endoglycan (Podxl2). Binding profiles for tumor versus normal cells were generated to enrich for those that preferentially bound to Podxl on tumor cells. Ab VH and VL regions were subsequently cloned into expression vectors containing the constant regions of the rabbit, human, or rabbit/human chimeric heavy and light chains, respectively, in order to generate high-affinity anti-Podxl rabbit, humanized and rabbit/human chimeric IgG1 Abs.

Cell culture

HEK293, human umbilical vein endothelial (HUVEC), SKOV3, SUM149, PANC-1, A-172, MIAPACA and MDA-MB-231 cells were obtained from ATCC. OV3331 patient tumor-derived EOC cell line was kindly provided by Dr. Mes-Masson from the University of Montreal. HEK293, human pancreatic adenocarcinoma (PANC-1, MIAPACA), A-172 and MDA-MB-231 cells were grown in Dulbecco’s Modified Eagle’s Me (DMEM, Gibco, #11965-092) supplemented with 10% fetal bovine serum (FBS) and 10 U/mL penicillin and streptomycin (P/S) (Gibco, #15140-122). HUVEC cells were harvested from donor umbilical cords (Human Ethics no. H10-00643), grown in Endothelial Cell Growth Medium-2 Bulletkit (LONZA, #CC-3162), and used between passages 2 and 8. Human ovarian cancer SKOV3 cells were grown in DMEM F-12 with 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Sigma, #D6421) supplemented with 10% FBS, 0.2 mM L-glutamine (Gibco, #25 030-081) and 10 U/mL P/S . Human breast cancer SUM149 cells were grown in DMEM F-12 with 15 mM HEPES supplemented with 5% FBS, 5 µg/mL insulin (Sigma, #234-291-2), 1 µg/mL hydrocortisone (StemCell Technologies, #07904) and 10 U/mL P/S. OV3331 cells were grown in complete OSE medium.36 All cell lines were maintained at 37°C, 5% CO2 and high humidity.

CRISPR/Cas9 plasmid design

To establish SKOV3, MIAPACA and MDA-MB-231 PODXL-KO cells, we followed a two-cut approach using clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas 9) technology. Target sites flanking the first exon were selected (combined cut size of 753 bp). Target sequences were designed using the Zhang’s lab online CRISPR design tool ( Oligonucleotides used to generate the guide RNAs (gRNAs) to edit the human PODXL gene were: g-PODXLup-FW (5’- caccgCCGCCCTGGAGCGCGACGGG-3’), g-PODXLup-RV (5’-aaacCCCGTCGCGCTCCAGGGCGGc-3’), g-PODXLdw-FW (5’-caccgGTGGAGACGAATCTACGCCC-3’), g-PODXLdw-RV (5’ aaacGGGCGTAGATTCGTCTCCACc 3’). Each target’s pair of annealed oligonucleotides was cloned into pSpCas9(BB)-2A-GFP (PX458) gRNA expression vector (Addgene #48138; 48138; RRID:Addgene_48138) following digestion with BbsI (10 U/µl, ThermoFisher Scientific, #ER1011) as previously described.37 These constructs were denominated pX458-Cas9-gPODXLup and pX458-Cas9-gPODXLdw, respectively. Sequences of all constructs were confirmed by Sanger sequencing.

Generation of CRISPR/Cas9-mediated PODXL-KO cells

SKOV3, MIAPACA and MDA-MB-231 cells (5×105) were co-transfected with 2 µg of both pX458-Cas9-gPODXLup and pX458-Cas9-gPODXLdw using Lipofectamine 3000 Transfection Reagent (ThermoFisher Scientific, #L3000015). Two days after transfection, cells were sorted for green fluorescent protein (GFP) expression. Three days post-sorting, cells were single-cell cloned in a 96-well plate. After 3–4 weeks, single colonies were divided in half; one half was used for propagation and colony maintenance while the other was used to assess the PODXL locus. A 983 bp fragment including the segment flanked by the gRNA target regions was PCR-amplified from genomic DNA using PODXL-CRISPR4-FW (5’-CTCCTCCCGAGTGGAGAGT-3’) and PODXL-CRISPR4-RV (5’-CTCCGGATTTGCTCGTAGTG-3’) primers. PCR products were verified using gel electrophoresis. Colonies with a 230 bp amplicon were selected and PODXL expression was assessed using immunoblotting and flow cytometry.

Flow cytometry

Cells were washed 1× with Ca2+-free and Mg2+-free HBSS (Gibco, #14170-112), incubated for 1–2 min at 37°C in a 0.25% trypsin solution, quenched with complete growth media, then centrifuged for 4 min at 394 g, washed 2× with flow cytometry staining (FACS) buffer (PBS, 2 mM EDTA, 5% FBS, 0.05% sodium azide) and transferred to a 96 well ‘v’ bottom plate. Cells were resuspended in 100 µL blocking buffer (FACS buffer, 1 µg/mL of anti-CD16/CD32 (clone 2.4G), 2% rat serum) for 20 min at 4°C in the dark, then spun at 394g for 4 min and incubated in 100 µL primary Ab solution for 30 min at 4°C in the dark. Rabbit PODO8321 (2 µg/mL) and either rabbit or chimeric PODO447 (5 µg/mL) were used to detect Podxl. Rabbit IgG (5 µg/mL, Vector Laboratories, #I-1000-5) and mouse/human-chimeric pavilizumab (5 µg/mL, National Research Council (NRC) of Canada) were used as isotype controls. Next, cells were washed 3× with FACS buffer and resuspended in 100 µL of secondary Ab solution (Alexa Fluor 647 (AF647) donkey-anti-rabbit (2 µg/mL, Invitrogen, #A31573) or AF647 goat-anti-human (2 µg/mL, Jackson ImmunoResearch Laboratories, #109-605-098)) for 30 min at 4°C in the dark. Cells were washed 2× with FACS buffer and resuspended in FACS buffer containing propidium iodide (0.5 µg/mL, Life Technologies, #P3566). All flow cytometry data was acquired using a BD LSRII and analyzed using FlowJo software (BD Biosciences, Ashland).

Glycan array

Fabrication of the printed glycan array slides and high-throughput analysis were performed as previously described.38 Printed glycochips were incubated in blocking buffer (50 mM ethanolamine buffer, pH 8.5) for 1 hour at room temperature (RT). Slides were rinsed with PBS (3×, 30 s), deionized water (1×, 30 s), and incubated with 50 µg/mL of humanized PODO447 or human IgG1κ isotype control for 1 hour with gentle rotation (200 revolutions/min) in a sealed, humidified environment. Next, slides were washed with PBS-T (PBS, 0.05% Tween20, pH 7.4 (1×, 5 min)) and PBS (1×, 30 s), followed by a short centrifugation. Slides were incubated with goat antihuman IgG-Cy3 (Fc specific, 10 µg/mL, Sigma-Aldrich, #C2571) for 1 hour at RT. Slides were washed with PBS (3×, 30 s), deionized water (1×, 30 s), and dried by centrifugation (30 s). Fluorescent signals from the bound Ab were detected using ScanArray microarray scanner (PerkinElmer). Scanned images were analyzed using ScanArray Express software. Spots were identified using automated spotfinding with manual adjustments for occasional irregularities. Spot relative fluorescent (RFU) intensity was determined by subtracting the median pixel intensity of the local background from the average pixel intensity within the spot. Triplicate spots were averaged and the mean value of RFU intensity was used.

Enzymatic treatment

SKOV3 cells (2.5×106) were washed 1× with PBS, incubated in enzyme-free dissociation buffer (ThermoFisher Scientific, #13 151-014) for 15 min, centrifuged at 394g and washed 1× with assay buffer (Ca2+/Mg2+-free DMEM/F12 (Sigma, #D9785), 2 mM CaCl2, 0.1% BSA). Aliquots were resuspended into three treatment conditions: control (500 µl; assay buffer), neuraminidase (500 µL; 5 U/mL of neuraminidase (New England BioLabs, #P0720S) in assay buffer), or endopeptidase treatment (500 µL; 0.24 mg/mL of endopeptidase (Cedarlane, #CLE100) in assay buffer). Cells were treated for 45 min at 37°C, and tubes were inverted at 10 min intervals. Cells were then centrifuged at 394g for 5 min and washed 2× with assay buffer prior to staining with rabbit PODO83, PODO447 and isotype control, and flow cytometric analysis.

Full-length and Podxl-ΔMucin mutant-expressing SKOV3 epithelial OC cells

Human full length (WT) and Podxl-ΔMucin sequences were synthesized as gBlock gene fragments purchased from Integrated DNA Technologies, and assembled and cloned into the pTT22 expression vector (NRC of Canada) using Gibson assembly.39 Sequences were designed to include mouse CD43 signal peptide (SP) and a FLAG-tag motif (sequences in online supplemental table 1, online supplemental figure 1). Podxl-ΔMucin mutant was generated by substituting Podxl’s mucin domain for CD43’s SP and FLAG-tag motif. Plasmids containing the constructs were confirmed by Sanger sequencing. SKOV3 (5×105) PODXL-KO cells were stably transfected with 2 µg of either WT- or Podxl-ΔMucin-pTT22 using Lipofectamine 3000 Transfection Reagent (ThermoFisher Scientific, #L3000015), and maintained under puromycin selection (5 µg/mL, Gibco, #A1113802). Expression was analyzed using western blotting and flow cytometry, and cells were sorted to enrich for construct-expressing cells.

Supplemental material

Supplemental material


OC tissue microarrays (TMA) were obtained from the Genetic Pathology Evaluation Centre TMA Database (Vancouver, Canada), and stained with either rabbit-PODO83 (2 µg/mL) or rabbit-PODO447 (5 µg/mL). Tissue cross-reactivity (TCR) TMAs were purchased from US Biomax (#MNO1021) and stained with either Rbt/Hu-chimeric PODO447-BIOT (5 µg/mL) or Mo/Hu-chimeric palivizumab-BIOT control (5 µg/mL). Additionally, humanized PODO447 was sent to Charles Rivers Laboratories for independent testing of Ab TCR. See online supplemental materials and methods for a detailed staining protocol.

Supplemental material

Immunohistochemical scoring

OC TMAs (219 cases) were blindly scored by four independent observers (DCH, KW, CDR), including a pathologist (MK), compared and combined. The TCR studies were performed by two independent facilities, including the preclinical contract research organization Charles River Laboratories (CRL) where the analysis was carried out by an independent pathologist under good laboratory practices. See online supplemental materials and methods for a detailed description of the scoring process.

Generation of Ab–drug conjugates

Monomethyl auristatin E (MMAE) linked to a synthetic dipeptide linker (MC-vc-PAB-MMAE) was used for conjugation with rabbit/human-chimeric PODO447 (NRC of Canada). Mouse/human-chimeric palivizumab was also conjugated with MMAE (MC-vc-PAB-MMAE) and served as the control (NRC). All conjugates were verified by high-performance liquid chromatography for the drug to Ab ratio (DAR) target of 4.0.

Ab–drug conjugates in vitro cytotoxicity

On day 0, OV3331, SKOV3 WT and PODXL-KO cells (2.5×103 per well) were plated on 96-well plates in 100 µL culture medium and allowed to adhere overnight. On day 1, a 5× stock solution of each mAb-antibody–drug conjugate (ADC) concentration to be tested was prepared in a stepwise 1:3 serial dilution series in cell culture medium, and 25 µL of each dilution was added to cells in triplicate. Treated cells were cultured at 37°C, 5% CO2 and high humidity for 144 hours. On day 6, the thiazolyl blue tetrazolium bromide (MTT) assay was used to determine relative cytotoxicity. Briefly, 100 µL of MTT (1 mg/mL, ThermoFischer Scientific, #AC158990010) in culture medium was added to the cells and left to incubate for 3 hours at 37°C. Next, MTT media was removed and 50 µL of dimethyl sulfoxide (DMSO, Sigma, #276855) was added to the cells and allowed to incubate for 15 min at RT, protected from light and with mild shaking. Absorbance was then read at 570 nm. The per cent viability was calculated as follows: (1-(absorbance of treated samples/average absorbance of control samples)) × 100. Average relative cytotoxicity was calculated and statistical analysis was performed using two-way analysis of variance in GraphPad Prism software. A p value less than 0.05 was considered statistically significant.


Development of a novel tumor-restricted anti-Podxl Ab

We developed a panel of anti-Podxl mAbs that recognize the extracellular domain of Podxl using SLAM.35 Briefly, rabbits were immunized with A-172 cells, a human glioblastoma cell line that expresses high levels of tumor-glycosylated Podxl. Supernatants from splenic primary B cell clones were screened for reactivity to cell surface-expressed Podxl and minimal cross reactivity to Podxl-deficient cells or cells expressing related family members CD34 and endoglycan.

Next, we screened Podxl-reactive B cell clones against Podxl-expressing human tumor cell lines from diverse tissue origins including SKOV3 (ovarian), A-172 (glioblastoma), MDA-MB-231 (breast) and MIAPACA (pancreatic) and counter-screened against normal HUVEC to identify tumor-specific Abs. We selected two mAbs for further characterization. The previously described PODOC1 (PODO83)21 showed high affinity for Podxl on both tumor and normal cells. Conversely, PODO447 showed high affinity only for Podxl expressed on tumor cell lines (figure 1A, online supplemental figure 2). To confirm Podxl-specificity of PODO447 and PODO83, we ablated Podxl expression in three PODO447/83-positive tumor lines (SKOV3, MIAPACA and MDA-MB-231) using CRISPR-mediated gene deletion. We observed complete loss of PODO447 and PODO83 binding on all CRISPR-PODXL-knockout (PODXL-KO) cells compared with the parental (WT) lines (figure 1B), thus confirming that both PODO447 and PODO83’s epitopes require expression of the Podxl protein.

Supplemental material

Figure 1

Development of novel antipodocalyxin antibodies. (A) Flow cytometric PODO83 (blue lines) and PODO447 (red lines) binding profiles of Podxl-positive normal (HUVEC) and tumor cells (A-172, SUM149, PANC-1). (B) Flow cytometric histograms showing PODO83 (blue lines) and PODO447 (red lines) immunoreactivity to Podxl-positive (WT, solid lines) or -deficient (PODXL-KO, dashed lines) ovarian (SKOV3), pancreatic (MIAPACA) and breast (MDA-MB-231) cancer cells. WT, wild type.

To further assess the specificity of PODO447 for tumor Podxl, we evaluated the reactivity of PODO447 and PODO83 to normal human kidney, where Podxl is highly expressed by glomerular podocytes.15 Notably, in formalin-fixed, paraffin-embedded sections of the kidney cortex, PODO83 staining was readily evident on the glomerulus and vascular endothelium, whereas PODO447 staining was undetectable (figure 2A). Next, we evaluated PODO447’s cross reactivity on an array of normal human histological sections. While PODO447 demonstrated intense staining on cryosections of control A-172 cells (online supplemental table 2), it was found to be minimally reactive on normal tissue (figure 2B, online supplemental table 3). We detected rare-to-occasional reactivity (<10%) on mucosal epithelial cells in breast, fallopian tube and endometrium. In addition, we observed occasional weak cytosolic positivity in cells of the salivary gland and adrenal gland, stomach, rectum, pancreas and kidney cortex. This intracellular reactivity was also evident in tissues stained with an isotype-matched negative control, arguing against specific reactivity. Importantly, we found minimal expression of the PODO447 epitope on normal endothelia of all tissue sites examined. The sole exception was occasional vessel-like structures restricted to the kidney medulla that are likely vasa recta. In addition, PODO447’s minimal normal TCR was independently confirmed by the CRL at both low (2 µg/mL) and high (20 µg/mL) Ab concentrations (online supplemental table 4). Concordantly, CRL found that PODO447 stained the cytoplasm of a very low number of podocytes, rare cells of the mucosal epithelia of the fallopian tube and small intestine, and rare cells of the skin sweat gland epithelia. Therefore, we conclude that PODO447 does not recognize the Podxl core protein (or other epitopes) expressed by most, if not all, normal tissue (figure 2B, online supplemental tables 3 and 4).

Figure 2

Representative images of healthy human tissue stained with PODO447. (A) Normal human kidney serial sections stained with either PODO83 or PODO447. Note the strong PODO83 staining (brown color) present on the podocytes in the glomerulus and on vascular endothelia (arrows). (B) Examples of normal human tissue sections stained with PODO447. Scale bars=100 µm.

PODO447 binds selectively to the mucin domain of tumor-expressed Podxl

Given that both PODO83 and PODO447 bind to the extracellular domain of the protein, we hypothesized that PODO447 may bind to a region subject to post-translational modifications and likely within the mucin domain. To test this, we performed a series of enzyme degradation assays using PODO83- and PODO447-reactive SKOV3 OC cells (figure 3A). Treatment of SKOV3 cells with neuraminidase, which removes terminal sialic acids on glycoproteins, did not affect binding of either Ab. However, O-sialoglycoprotein endopeptidase, a proteolytic enzyme that specifically cleaves proteins bearing clusters of negatively charged sugars, significantly attenuated PODO447, but not PODO83, immunoreactivity (figure 3A). From this, we conclude that the PODO447 epitope lies within the mucin domain.

Figure 3

PODO447 recognizes a glycomotif on Podxl’s mucin domain. (A) Flow cytometric histograms of SKOV3 wild-type (WT) cells treated with either assay buffer (control), neuraminidase (which removes the terminal sialic residues) or O-sialoglycoprotein endopeptidase (which cleaves the mucin domain). Cells were then stained with either PODO83 (blue) or PODO447 (red). (B) Flow cytometric histograms showing PODO83 (blue lines) and PODO447 (red lines) immunoreactivity to SKOV3 PODXL-KO cells re-expressing the WT podocalyxin (Podxl) (WT Podxl) protein or a Podxl-mutant lacking the mucin domain (ΔMucin Podxl).

To further confirm this result, we reconstituted SKOV3 PODXL-KO cells with either the full length, wild-type (WT) protein or a mutant lacking the N-terminal mucin domain (ΔMucin), and evaluated the ability of these to restore the PODO83 and PODO447 epitope (figure 3B). Whereas both Abs bound to PODXL-KO cells expressing the WT protein, only PODO83 (but not PODO447) reacted with cells expressing the Podxl-ΔMucin protein. From these data, we conclude that the PODO83 epitope is present within the extracellular stalk domain of Podxl, whereas PODO447 binds selectively to an epitope within the glycosylated mucin domain.

PODO447 recognizes a rare tumor-restricted glycoepitope

Since PODO447 showed selective binding to the mucin domain of Podxl on tumor cells, we hypothesized that it may react with a modified glycoepitope generated exclusively by tumor cells. To gain further insights into its specificity, we probed a well-characterized glycan array40 with PODO447 to map potential glycoepitopes (table 1). This printed array includes 320 distinct glycan structures and serves as an ideal platform for identifying binding structures required for carbohydrate recognition.41 PODO447 exhibited the highest affinity to a rare, terminal N-acetylgalactosamine-beta-1 (GalNAcβ1) motif on O-linked glycans (table 1 and online supplemental table 5). This glycomotif has been previously found on cancer-associated glycoepitopes such as globotetraose (Gb4, P)42 and LadiNAc.43 In addition, PODO447 showed significant binding to the Tn antigen (GalNAcα1-OSer), which has previously been reported to be abundantly expressed on Podxl in the kidney.44 However, the Tn antigen is most likely not involved in PODO447’s recognition of cancer cells, as we observe a very low number of Tn-positive cells on cell lines expressing high levels of the PODO447 epitope (online supplemental figure 3). In addition, the anti-Tn Ab, clone 5F4, did not interfere with the ability of PODO447 to bind its epitope (online supplemental figure 4). To the best of our knowledge, this is the first time the GalNAcβ1 motif has been observed on Podxl, and PODO447 represents the first mAb against it.

Supplemental material

Supplemental material

Table 1

PODO447 recognizes a rare glycomotif

PODO447 drug conjugate results in tumor cytotoxicity

The discovery that PODO447 recognizes a novel tumor epitope on Podxl encouraged us to investigate the potential use of PODO447 as a cancer therapeutic. We first assessed PODO447 as an unconjugated monotherapy and observed no effects of this mAb as a single agent in vitro or in vivo (online supplemental figure 5). These results encouraged us to investigate PODO447 as the targeting arm of an ADC immunotherapeutic. We chose MMAE as our toxin payload, a well-known tubulin polymerization inhibitor that has been used as a cancer therapy due to its potent antitumor activity. Next, we conjugated chimeric PODO447 and control palivizumab mAbs to MMAE using a valine-citrulline (val-cit) proteolytically cleavable linker, resulting in Vedotin (Val-Cit-MMAE) ADCs (figure 4A). The cytotoxic effects of both conjugates were determined in a long-term (144 hours) drug exposure assay on OV3331, and SKOV3 WT and PODXL-KO cells (figure 4B–D). We observed a nine-fold reduction in cell viability in PODO447-ADC-treated OV3331 cells when compared to the control (figure 4C). This cytotoxic effect was due to specific drug delivery as we did not observe a reduction in cell viability on palivizumab-ADC-treated cells. To further confirm the specificity of PODO447 ADC to Podxl-expressing tumor cells, we treated SKOV3 WT and PODXL-KO with the vedotin conjugates. We observed a three-fold reduction in the viability of SKOV3 treated with PODO447-ADC but no effect on the PODXL-KO cells treated with PODO447-ADC (figure 4D). As expected, neither line responded to control-ADC-treatment (figure 4D). From these experiments, we conclude that PODO447 can effectively deliver, with precise specificity, a toxic payload to ovarian tumor cells expressing an appropriately tumor-glycosylated form of Podxl.

Supplemental material

Figure 4

PODO447 antibody-drug conjugate in vitro cytotoxicity. (A) Representative image of mAb-Vedotin conjugate structure (created with (B) Western blot showing PODO447 binding to lysates from OV3331, and SKOV3 WT and PODXL-KO cells. (C) In vitro cytotoxic effect of PODO447 and palivizumab–vedotin conjugates on OV3331 patient-derived ovarian high-grade serous cancer cells (p<0.001). (D) In vitro cytotoxicity of control and PODO447-ADC on SKOV3 wild-type (WT) and PODXL-KO cells (p<0.001). Representative experiments are shown, and the values indicate the mean±SD. MMAE, monomethyl auristatin E.

PODO447 as a therapeutic candidate for OC

The finding that PODO447 recognizes a highly unusual tumor-restricted residue present on Podxl that does not cross-react with normal human tissues and could be used to deliver a toxic payload prompted us to further evaluate possible PODO447 therapeutic indications. The Podxl core protein is known to be expressed at high levels in ~90% of tubo-ovarian high-grade serous ovarian carcinomas (HGSOC), where cell surface localization is a strong predictor of poor outcome.22 Given the high lethality of HGSOC tumors, we carried out a detailed evaluation of the PODO447 epitope expression by these malignancies in an effort to evaluate the potential of PODO447 as a new immunotherapy for this cancer. We immunostained a TMA consisting of 219 cases of OC with PODO447 (TMA clinicopathological characteristics in online supplemental table 6). Each case on the TMA was initially scored based on the percentage of cells stained, with a scoring scale of 0 (negative, <1%), +1 (intermediate, 1%–50%) and +2 (high, >50%; table 2). Tumors scored as +1 and +2 were grouped as PODO447 positive. Of 219 cases, 144 (65.8%) were PODO447 positive. Positivity was not correlated with either the International Federation of Obstetrics and Gynecology stage or disease-free survival across the entire OC cohort (table 2, data not shown).

Table 2

PODO447 expression and localization within the tissue microarray cohort

We did note, however, that PODO447 reactivity across the major OC histotypes was significantly different. While only 40% of the mucinous carcinomas were PODO447 positive, the majority of endometrioid (74.1%), clear cell (68.0%), low-grade serous (75.0%) and HGSOC (65.8%) were PODO447 positive.

We have previously shown that cell surface localization of Podxl (vs cytoplasmic localization) is associated with decreased disease-free survival in HGSOC.22 Accordingly, we also scored PODO447’s predominant localization (cytoplasmic vs membranous) among the PODO447-positive cases on the TMA (table 2, figure 5). Overall, 115 (79.9%) of the 144 PODO447-positive cases exhibited membranous PODO447 staining (table 2, figure 5B). The remaining 29 cases exhibited diffuse, cytoplasmic staining (table 2, figure 5C). Unfortunately, due to the lower representation of mucinous and low-grade serous tumors in the TMA, we were unable to infer any meaningful prognostic conclusions about PODO447 localization in these histotypes. However, 19 of 20 (95.0%) endometrioid, 14 of 17 (82.4%) clear cell and 78 of 102 (76.5%) HGSOC tumors exhibited cell-surface PODO447-positive staining. Given that HGSOC is the most prevalent and lethal OC histotype,2 45 46 the cell surface reactivity of PODO447 with the majority of these tumors bodes well for this mAb’s utility in targeting and treating this unmet clinical need.

Figure 5

PODO447 differentially recognizes high-grade serous ovarian carcinomas (HGSOC) in a tumor microarray. Representative HGSOC tumor sections stained with PODO447 (brown color) that were scored as (A) negative (B) positive (membranous staining) or (C) positive (cytoplasmic) (see inset for higher magnification). Scale bars=100 µm.


Podxl is a member of the CD34 family of sialomucins, a family of transmembrane proteins that has been shown to play a role in modifying cell adhesion and making cells more mobile and invasive.47 48 Interestingly, Podxl is frequently upregulated in a variety of cancers and invariably correlates with poor outcome.20–30 In those studies where its oncogenic function has been evaluated in detail, Podxl has been shown to play a critical role in metastatic progression; gene inactivation or dampening of its mRNA expression cripples the ability of tumor cells to metastasize in xenografted mice.20 29 32 Thus, as a membrane protein involved in tumor progression, together with our previous study showing that Abs targeting its extracellular domain can delay primary tumor growth and block metastasis in mice,21 Podxl stands out as a promising target for immunotherapy. Further development of a Podxl-targeted therapeutic Ab has been hampered, however, by concerns over potential toxicity since Podxl is also normally expressed at high levels by vascular endothelia and kidney podocytes. Accordingly, in this study we sought to screen for a novel mAb with high specificity for a tumor glycoform of Podxl, and lack of reactivity with any normal cells. PODO447 emerged as uniquely fulfilling these key criteria. This mAb recognizes an array of human tumor cell lines while exhibiting minimal activity with normal cell types or tissues, including those that express the Podxl core protein at high levels. Specifically, we observed no reactivity of PODO447 with kidney podocytes and, with the sole notable exception of vessel-like structures in kidney medulla that appear to be vasa recta (under investigation), we observed minimal binding of PODO447 to any other peripheral vessels. Although we observed rare and weak PODO447 reactivity with the mucosal epithelia of the breast, fallopian tube and intestinal track, as well as the parenchyma of the adrenal, salivary and sweat glands, the level and frequency of this reactivity was low and could, in fact, represent spurious cross-reactivity since, in most cases, a similar staining pattern was also observed in the staining control. Moreover, the rare staining of these normal epithelial cells was observed to be largely cytoplasmic making it unlikely that this compartment would be accessible to circulating PODO447 in vivo. Importantly, these results have been independently confirmed by a preclinical CRO which speaks to the reproducibility and reliability of our findings.

With regards to therapeutic use of PODO447-based agents, epithelial ovarian cancer has emerged as an extremely promising avenue of further exploration. The Podxl core protein is known to be expressed at robust levels by the majority of high-grade serous carcinomas,22 the most prevalent histotype of OC49 for which the prognosis is poor and antigen-specific therapeutic options are extremely limited.45 46 We found that a high percentage of such HGSOC tumors express the PODO447 glycoepitope, thus offering a large population who could benefit from treatment. As shown in this study, coupling of PODO447 with various cytotoxic compounds to selectively target neoplastic cells could offer a novel therapeutic approach with minimal toxicity to normal tissues, an issue that plagues most traditional chemotherapy treatments.

Although we have explored the reactivity of PODO447 in OC in detail, further studies on other forms of cancer could widen the scope of its potential therapeutic use. For example, Podxl is known to be expressed by a high percentage of colon, brain and pancreatic tumors and thus, provided they share the appropriate post-translation modification, they too could be promising avenues for targeted therapeutic intervention using this Ab. As with any therapy, a nagging concern is the ability of cells to become resistant through down-regulation of the target antigen. However, because we have previously shown that Podxl plays a direct functional role in endowing metastatic cells with rare tumor initiating capacity, resistance may be less of an issue for this target.21 32 Indeed, one could speculate that targeting the PODO447-expressing fraction of tumor cells may selectively eliminate the subset of cells with the highest metastatic capacity, making it a more targeted therapy for this elusive subset of cells than standard chemotherapy (currently under investigation).

Another potential concern for PODO447, in particular, is the emergence of cells that have lost the glycotransferases required to generate the PODO447 epitope. Yet here, too, the ability to become resistant will depend on the functional significance of the unusual glycosylation on the PODO447 epitope. The GalNAcβ1 glycomotif that comprises part of this epitope is extremely unusual in normal eukaryotic settings. However, similar glycan structures such as the LacdiNAc-type (GalNAcβ1-4GlcNAc) motifs and the P antigen (Gb4) have previously been identified in ovarian cancer tissue.42 43 Thus, these epitopes may have an important functional role in tumor cell spread. If this were indeed the case, one could envision that targeting a rare PODO447 subpopulation of tumor cells would have an outsized role in managing the cancers by targeting cells most likely to spread. To this end, we are currently working to test the therapeutic efficacy of PODO447 coupled to toxins and radioisotopes in xenograft mouse tumor models.

Finally, the PODO447 epitope could offer promise as a new target for chimeric antigen receptor T cell (CAR-T)-based therapies. Although CAR-T therapy has been transformative for hard-to-treat B cell malignancies (B cell leukemia and some B cell lymphomas), to date this approach has not been exploited widely for other malignancies and, in particular, for solid tumors. To a large extent, this is due to the lack of appropriate tumor-specific epitopes. In this regard, it is noteworthy that the success of CD19-specific CAR-T therapies for B cell malignancies largely reflects the ability of patients to survive the complete ablation of both the tumor and the normal Ab producing B cell compartment. From this vantage point, PODO447, as a highly tumor-restricted mAb, may offer an unprecedented opportunity to extend the promise of this approach to ovarian cancers and other tumors.


PODO447 is a novel Podxl-targeting mAb that binds to a unique tumor-restricted glycoepitope with high specificity. Unlike other anti-Podxl Abs, PODO447 does not recognize Podxl expressed on healthy human tissue. Therefore, due to its potentially favorable safety profile, this study supports further development of PODO447 as a therapeutic agent.


The authors are very grateful to Anna von Rossum, Patrick Chan, Bradley Hedberg, John Babcook, and all the members of the Biologics Division at CDRD for the development and validation of the Abs; to Tate Goodman and Alannah Wilson for their technical contributions characterizing the PODXL-KO cell lines; to Anne-Marie Mes-Masson for kindly providing the patient-derived OV3331 cell line; to David Huntsman, Samuel Leung and Ingrid Barta for providing expert technical advice; and to the Biomedical Research Center core members R. Dhesi (safety), M. Williams and B. Silva (Abs). They thank Alissa Cait, Jessica Cait and Christine Eisner for their critical reading of the manuscript.


Supplementary materials


  • Contributors DCH designed and performed most experiments, analyzed and interpreted data, and was the primary author of this manuscript. MRH assisted with experimental design and manuscript writing. PD created the SKOV3 and MIAPACA PODXL-KO cell lines, initiated the enzymatic treatment experiments, and assisted in flow cytometry assays. PB, IS, CBG and EC assisted with the characterization of the antibodies studied herein. OB performed the glycan array experiments and analysis. MK and KW assisted with the ovarian carcinoma TMA immunohistochemical scoring, YL assisted in flow cytometry assays and CBG contributed the ovarian TMAs. CR and KM were key contributors to the experimental concept and design. All authors approved the final manuscript.

  • Funding This research was supported by the Canadian Institutes of Health Research (Grant Number: PJT-166180), the Canadian Cancer Research Institute (Grant number: 704344), the Center for Blood Research Graduate Award Program, Impact Grant from the Stem Cell Network Center of Excellence and the Danish National Research Foundation (Grant number: DNRF107).

  • Competing interests The authors are inventors of a pending patent application on PODO447 and methods of using the same (US20180296673A1). MRH, PB, IS, CBG, KM and CR are inventors of a pending patent application on PODO83 and methods of using the same (US20190367606A1). KM and CR possess an awarded patent on podocalyxin as a prognostic marker in cancer (US9309323B2).

  • Patient consent for publication Not required.

  • Ethics approval This study was performed in consideration with the Tri-Council Policy Statement of Ethical Conduct for Research involving Humans (TCPS 2). Animal experiments were performed humanely based on recommendations of the Canadian Committee on Animal Care with approval of the University of British Columbia’s Animal Care Committee (A16-0007, to KM).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. All data supporting the results presented in this study is included and discussed in the article and its supplementary figures. Additional data not directly relevant for the study presented here will be made available upon reasonable request to the corresponding author.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.